In May, 2019, following early results of the ADMIRAL trial (4), the FDA approved gilteritinib for the treatment of relapsed or refractory FLTmut+ AML with a detectable FLT3 mutation (15). The gene discussed is FLT3; the disease is acute myeloid leukemia.